Currency In USD
| Previous Close | 5.45 |
| Open | 5.89 |
| Day High | 6.07 |
| Day Low | 5.69 |
| 52-Week High | 6.07 |
| 52-Week Low | 2.2 |
| Volume | 643,317.4 |
| Average Volume | 357,348 |
| Market Cap | 358.09M |
| PE | -6.16 |
| EPS | -0.97 |
| Moving Average 50 Days | 4.42 |
| Moving Average 200 Days | 4.29 |
| Change | 0.53 |
Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT
GlobeNewswire Inc.
Mar 03, 2026 1:00 PM GMT
NEW HOPE, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with marke
Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics
GlobeNewswire Inc.
Jan 12, 2026 2:00 PM GMT
$11 million in proceeds expected to be received during 2026, with remainder of expected proceeds to be received in future revenue earnoutsVivasure Medical Limited (“Vivasure”) has been a strategic holding of Orchestra BioMed since the Company’s forma
Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting
GlobeNewswire Inc.
Dec 08, 2025 12:00 PM GMT
Joint presentation by Orchestra BioMed and Medtronic leadership to discuss ongoing strategic collaboration for development and commercialization of AVIM Therapy for treatment of uncontrolled hypertension in patients indicated for a pacemaker NEW HOPE